Genetics

Mars, Incorporated Enters Exclusive Discussions to Acquire the Entire Stake in French Veterinary Diagnostics Businesses Cerba Vet and ANTAGENE Held by the Cerba HealthCare Group

Retrieved on: 
Friday, May 3, 2024
Veterinary, Biotechnology, Pets, Health, Medical Devices, Wearables, Mobile Technology, Technology, Consumer, Genetics, Laboratory, Pet, Biodiversity, Veterinarian, Hematology, Endocrinology, Serology, Growth, Cat, DNA, Science, Microbiology, Chemistry, Acquisition, Dog, Horse, Veterinary medicine

Mars, Incorporated today announced that it has entered into exclusive discussions with Cerba HealthCare with a view to acquiring Cerba HealthCare’s ownership stake in Cerba Vet and ANTAGENE.

Key Points: 
  • Mars, Incorporated today announced that it has entered into exclusive discussions with Cerba HealthCare with a view to acquiring Cerba HealthCare’s ownership stake in Cerba Vet and ANTAGENE.
  • Headquartered in Massy, France, Cerba Vet is a network of six veterinary diagnostics laboratories in France and Switzerland.
  • Cerba Vet is recognized by veterinarians in France for its medical expertise and pioneering continuous education program, the Cerba Vet College, with weekly live webinars and several practical sessions annually.
  • Cerba Vet and ANTAGENE complement Antech, the veterinary diagnostics business of Mars Science & Diagnostics, which provides a full portfolio of diagnostics solutions to veterinary professionals around the world.

MiRNA Sequencing and Assay Market Research 2024: Robust Growth with Emerging Trends in Personalized Medicine and Advancements in Sequencing Technologies - Global Forecasts to 2029 - ResearchAndMarkets.com

Retrieved on: 
Friday, May 3, 2024
Biotechnology, Genetics, Health, Cancer, Genomics, Prognosis, Cardiology, RNA, Traction, Research, NGS, Disease, Patient, Neurology, Data analysis, Gene expression, Diagnosis, Messenger, Biomarker, Molecular biology, Immunity, Risk assessment, Drug discovery, Medicine, Algorithm, Medical imaging

One of the primary drivers of the global miRNA sequencing and assay market is the rising demand for personalized medicine and precision diagnostics.

Key Points: 
  • One of the primary drivers of the global miRNA sequencing and assay market is the rising demand for personalized medicine and precision diagnostics.
  • This has led to a surge in the adoption of miRNA sequencing and assay technologies in both research and clinical settings.
  • The integration of bioinformatics tools has emerged as a significant driver in boosting the Global MiRNA Sequencing and Assay Market.
  • The rising interest in personalized medicine has emerged as a powerful catalyst in boosting the Global MiRNA Sequencing and Assay Market.

DecisionDx®-SCC Significantly Improves Prediction Accuracy of Metastatic Events after Mohs Surgery in New Study of Patients with High-Risk Cutaneous Squamous Cell Carcinoma Tumors of the Head and Neck

Retrieved on: 
Friday, May 3, 2024
Surgery, Genetics, Clinical Trials, Biotechnology, Biometrics, Health, Pharmaceutical, General Health, Oncology, Radiation, Mohs, NCCN, Mohs surgery, American College, CME, ACMS, Abstract (summary), Neck, National Comprehensive Cancer Network, SCC, Patient, Metastasis, Neoplasm, Head, BWH

“In most cases, once a tumor is removed completely, the patient is in the clear.

Key Points: 
  • “In most cases, once a tumor is removed completely, the patient is in the clear.
  • This study included 417 patients who received definitive Mohs surgery to remove high-risk SCC tumors of the H&N with reported clear margins.
  • Presenting authors will be available to answer questions regarding their posters on Saturday, May 4, from 12-1 p.m. Mountain Standard Time.
  • Abstracts will also be in ACMS' CME & Abstract Book and available for online viewing via the Planstone abstract site.

Gene Therapy Pioneer Jerry R. Mendell, M.D., Named to Inaugural TIME100 Health List of the 100 Most Influential People in Global Health

Retrieved on: 
Friday, May 3, 2024
Health, Neurology, Genetics, Research, Science, Pharmaceutical, Biotechnology, Neuromuscular disease, SRPT, National academy, DSM-IV codes, Hospital, Muscular dystrophy, Book, SMA, Cell, Duchenne, Disease, TIME, Patient, Sarepta Therapeutics, Gene, Society, Nationwide, Duchenne muscular dystrophy, Head, Therapy, Global health, Pharmaceutical industry

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that TIME named renown neuromuscular researcher, physician and gene therapy pioneer Jerry R. Mendell, M.D., to the inaugural 2024 TIME100 Health, a list of 100 individuals who most influenced global health this year.

Key Points: 
  • Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that TIME named renown neuromuscular researcher, physician and gene therapy pioneer Jerry R. Mendell, M.D., to the inaugural 2024 TIME100 Health, a list of 100 individuals who most influenced global health this year.
  • The TIME100 Health list recognizes the impact, innovation, and achievement of the world’s most influential individuals in health.
  • In addition to recognition on the TIME100 Health list, Dr. Mendell is a 2024 recipient of the King Faisal Prize Laureate in Medicine.
  • He is also a published author of more than 400 peer-reviewed articles and books about skeletal muscle disease, peripheral nerve disorders and gene therapy.

CareDx Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Retrieved on: 
Friday, May 3, 2024
Health, Surgery, Health Technology, Genetics, Managed Care, General Health, Biotechnology, Caregiver, Transplant, Compensated emancipation, Medicine, Patient, Employment

The RSUs were granted pursuant to the Company’s 2019 Inducement Equity Incentive Plan, which was approved by the Compensation Committee of the Board of Directors in August 2019 under Nasdaq Listing Rule 5635(c)(4).

Key Points: 
  • The RSUs were granted pursuant to the Company’s 2019 Inducement Equity Incentive Plan, which was approved by the Compensation Committee of the Board of Directors in August 2019 under Nasdaq Listing Rule 5635(c)(4).
  • RSUs for an aggregate of 43,350 shares vest over four years, with 25% of the RSUs vesting on the first anniversary of the applicable vesting commencement date, and the balance vesting annually thereafter in three equal installments, subject to the grantee’s continued service through each applicable vesting date.
  • RSUs for 1,000 shares vest over two years, with 50% of the RSUs vesting on each of the first two anniversaries of the applicable vesting commencement date, subject to the grantee’s continued service through each applicable vesting date.
  • RSUs for 2,000 shares vest on the one-year anniversary of the applicable vesting commencement date, subject to the grantee’s continued service through such date.

Global RNAi Therapeutics Market Insights & Forecasts with Potential Impact of COVID-19 2024-2028 Featuring Sanofi, Alnylam, Arrowhead, Arbutus Biopharma, Benitec Biopharma, Sirnaomics - ResearchAndMarkets.com

Retrieved on: 
Friday, May 3, 2024
Biotechnology, Pharmaceutical, Genetics, Health, Molecule, MicroRNA, Investment, RNA interference, Hospital, Infection, RNA, Research, Liver, HTS, Therapy, DSM-IV codes, COVID-19, Prevalence, Row

The "Global RNAi Therapeutics Market (By Molecule Type, Application, End-User & Region): Insights & Forecast with Potential Impact of COVID-19 (2024-2028)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global RNAi Therapeutics Market (By Molecule Type, Application, End-User & Region): Insights & Forecast with Potential Impact of COVID-19 (2024-2028)" report has been added to ResearchAndMarkets.com's offering.
  • The global RNAi therapeutics market is expected to record a value of US$1.39 billion in 2028, progressing at a CAGR of 9.98%, over the period 2024-2028.
  • Whereas, the global RNAi therapeutics market is split into research & academic laboratories and hospitals & diagnostic laboratories, in terms of end-user.
  • The report provides a comprehensive analysis of the global RNAi therapeutics market segmented on the basis of molecule type, application, end-user and region, with potential impact of COVID-19.

Sampled Named One of the First Olink® Certified Service Providers

Retrieved on: 
Friday, May 3, 2024
Research, General Health, Pharmaceutical, Oncology, Medical Devices, Genetics, Health Technology, Clinical Trials, Science, Biotechnology, Stem Cells, Health, Sample, Marketing, PEA, Certification

Proteomics technology is an important tool for studying diseases, providing crucial insights into their underlying molecular mechanisms.

Key Points: 
  • Proteomics technology is an important tool for studying diseases, providing crucial insights into their underlying molecular mechanisms.
  • Olink® Certified Service Providers are recognized for their commitment to delivering the highest quality standards, undergoing rigorous training and annual certification using concordance samples.
  • “We are proud to be one of the first Olink® Certified Service Providers and believe it highlights our dedication to pioneering health innovations.
  • “We are excited that Sampled has joined the Olink® Certified Service Provider Network as it underscores our shared goal of giving customers the highest quality tools for their biomarker discovery research.

Latus Launches with State-of-the-Art Gene Therapy Development Technologies, Two Lead Product Candidates, and an Initial $54 Million in Series A Financing

Retrieved on: 
Thursday, May 2, 2024
Biotechnology, Professional Services, Health, General Health, Pharmaceutical, Other Science, Research, Genetics, Science, Clinical Trials, Finance, Doctor of Philosophy, CNS, SVP, Translational medicine, MIT, Genzyme, Cochlea, Hereditary Disease Foundation, Harvard Medical School, Toxicity, HTT, Therapy, Merck, CLN2, Hospital, Safety, Biomedical Research, Samsung Biologics, CHOP, Samsung C&T Corporation, AAV, Koch Institute, Gene expression, Central nervous system, NHP, Program management, Cell, DSM-IV codes, Patient, Gene, Society, Einstein Medical Center Philadelphia, Annual general meeting, Massachusetts General Hospital, Pharmaceutical industry

Latus Bio, Inc. (“Latus”), a biotechnology company developing novel gene therapy candidates for disorders of the central nervous system (CNS), today announced its launch and an initial close of $54 million in Series A financing.

Key Points: 
  • Latus Bio, Inc. (“Latus”), a biotechnology company developing novel gene therapy candidates for disorders of the central nervous system (CNS), today announced its launch and an initial close of $54 million in Series A financing.
  • These limitations have led to the reliance on high-dose injections that cause off-target toxicity and difficulties in scalable manufacturing.
  • The Company’s management team is composed of experienced and respected leaders in gene therapy and neuroscience.
  • Her address will showcase the Company's progress and the vast potential of its technology to solve unmet needs in CNS gene therapy.

Karius Raises $100M Co-Led by Khosla Ventures, 5AM Ventures and Gilde Healthcare, to Expand Access to Advanced Genomic Diagnostics in Infectious Disease, Addressing Antimicrobial Resistance Crisis

Retrieved on: 
Thursday, May 2, 2024
Technology, Medical Devices, Medical Supplies, Infectious Diseases, Genetics, Clinical Trials, Biotechnology, Health, Artificial Intelligence, AbCellera, CFO, University, Cancer, SoftBank Vision Fund, Antimicrobial resistance, Bone marrow, HBM, Pneumonia, Head, Risk, Hospital, Metagenomics, Infection, Survival, AMR, Public, Eli Lilly, Khosla Ventures, Partnership, University of California, Research, Artificial intelligence, DNA, Partner (business rank), Transplant, Patient, Immunodeficiency, Eric Schmidt, General partnership, MD Anderson Cancer Center, Death, Growth, Pharmaceutical industry

Karius® , Inc., a world leader in genomic diagnostics for infectious disease, today announced it has secured $100 million in Series C funding.

Key Points: 
  • Karius® , Inc., a world leader in genomic diagnostics for infectious disease, today announced it has secured $100 million in Series C funding.
  • The round was co-led by Khosla Ventures and new investors 5AM Ventures and Gilde Healthcare.
  • The funding enables Karius to address increasing demand from healthcare providers to expand access to the Karius Test beyond the hospital setting.
  • Additionally, it will support research into the broader health implications of Karius’ microbial cell-free DNA technology beyond infectious diseases.

Twist Bioscience Reports Fiscal Second Quarter 2024 Financial Results

Retrieved on: 
Thursday, May 2, 2024
Technology, Biotechnology, Nanotechnology, Chemicals, Plastics, Health, Manufacturing, Pharmaceutical, Other Science, Research, General Health, Genetics, Health Technology, Science, Data Management, Twist, Doctor of Philosophy, Nucleic acid thermodynamics, Net, Genomics, Investment, Exome, Capital, Sequence, PIN, Depreciation, Silicon, Genetic variation, Growth, Twist Bioscience, NGS, Development, Administration, SynBio, Tax, UHT, Adjustment, Telephone, GAAP, Element, Gene, Tobacco

Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today reported financial results and business highlights for the second quarter of fiscal 2024 ended March 31, 2024.

Key Points: 
  • Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today reported financial results and business highlights for the second quarter of fiscal 2024 ended March 31, 2024.
  • Shipped products to 2,253 customers in the second quarter of fiscal 2024, compared to approximately 2,100 customers in the second quarter of fiscal 2023.
  • Shipped approximately 193,000 genes during the second quarter of fiscal 2024, compared with approximately 152,000 genes during the second quarter of fiscal 2023.
  • For the third quarter of fiscal year 2024, Twist provided the following financial guidance:
    For the fourth quarter of fiscal year 2024, Twist provided the following financial guidance:
    1For in vitro diagnostic use.